dwtx.com (DWTX): Rasio utang marang kapitalisasi buku

Logo korporat perusahaan Dogwood Therapeutics (DWTX)

Dogwood Therapeutics, Inc. (DWTX) generates revenue by developing nasal treatments for viral infections and fibromyalgia, competing for patents against major pharmaceutical behemoths. The debt concentration level within the balance sheet capitalization on GURU.Markets highlights borrowing dynamics, where the 0.00 indicator determines the metric's magnitude. The startup's operations are constrained by compliance with chemical disposal standards and basic energy conservation in its laboratories.

DWTX Dogwood Therapeutics: Utang marang nilai buku ing interval 10.10.2024 - 31.10.2026

Rincian metrik komprehensif lan analitis dwtx.com (DWTX)

- rega saiki lan proyeksi nilai saham:
Rega saham Dogwood Therapeutics|DWTX - Prakiraan konsensus analis
- data kapitalisasi bursa:
Nilai pasar Dogwood Therapeutics|DWTX - Nilai Dipunlarasaken Utang lan Kas
- indikator nilai buku ekuitas:
Aset Bersih saben Siji Saham Dogwood Therapeutics|DWTX - Aset Bersih Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku dwtx.com|DWTX - Total Aset Perusahaan
- informasi babagan utang lan solvabilitas:
Rasio Total Utang marang Ekuitas Dogwood Therapeutics, Inc.|DWTX - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Dogwood Therapeutics|DWTX - Utang perusahaan|Utang-utang marang kapitalisasi buku Dogwood Therapeutics|DWTX - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Dogwood Therapeutics|Indikator likuiditas cepet dwtx.com
- data bathi bisnis lan rasio investasi:
DWTX - Bathi resik
Ringkesan analitik perusahaan:Virios Therapeutics DWTX
Produk sing diprodhuksi Dogwood Therapeutics Inc.

This indicator measures the degree of business dependence on borrowed funds relative to equity. By analyzing the total debt-to-book capitalization ratio on the GURU.Markets platform, an investor assesses the financial stability of Dogwood Therapeutics, Inc. (DWTX). A high debt load amid fierce patent battles with pharma behemoths may signal liquidity risks. An increase in this metric often indicates undervalued assets or a threat of default, which ultimately determines the overall reliability of the asset.

Analisis perusahaan pesaing

Utang-utang marang kapitalisasi buku GILD (Gilead Sciences, Inc.)|Utang-utang marang kapitalisasi buku Cidara Corp CDTX|NVAX - Rasio utang marang kapitalisasi buku|Rasio utang marang aset resik CVAC (CureVac NV)|Valneva Pharma (VALN) - Rasio utang marang kapitalisasi buku|Utang marang nilai buku Vir Corp|SIGA (SIGA Technologies, Inc.) - Utang-utang marang kapitalisasi buku|Utang-utang marang kapitalisasi buku emergentbiosolutions.com|Utang marang nilai buku AVIR (Atea Pharmaceuticals, Inc.)|IVVD (invivyd.com) - Rasio utang marang aset resik|Enanta - Utang marang nilai buku|Inovio Pharma - Rasio utang marang kapitalisasi buku|HilleVax, Inc. - Utang-utang marang kapitalisasi buku|Utang-utang marang aset resik kalaristx.com KLRS|dyadic.com (DYAI) - Rasio utang marang kapitalisasi buku|NanoViricides - Rasio utang marang aset resik|Utang marang nilai buku TLPH|Utang-utang marang kapitalisasi buku Cocrystal Pharma Corp|Rasio utang marang kapitalisasi buku Traws Pharma, Inc. (TRAW)|Utang-utang marang aset resik qualigeninc.com|Utang-utang marang kapitalisasi buku ALVR (AlloVir)|VBIV: Rasio utang marang nilai buku|VIRI - Rasio utang marang kapitalisasi buku|Utang-utang marang nilai buku Vaxart, Inc.